Saranya Wyles, M.D., Ph.D.

So we can clear zombie cells and that is through products like senolytics and we can turn down the noise from zombie cell and that is through products called xenomorphics.

So there are actives that we are exploring through clinical trials right now.

There are over 50 clinical trials in the United States that are looking at senolytics and looking at the benefit of senolytics for different chronic diseases.

So there's a lot of research going on.

So there are some that are over-the-counter, like fisetin is over-the-counter.

You have to be careful with how you're taking it because it's post-dosing.

It's not meant to be taken daily.

So there are some over-the-counter flavonoids they're called, like supplements.

And then there are more medical-grade versions.

DNQ, dasatinib, and quercetin are the ones that are often in clinical trials.

Yeah.

So the quercetin, we have a study going on.

We actually partnered with University of Colorado and we're doing a study on sheep and looking at sheep wool.

And we've applied topical dasatinib and quercetin and seeing how the wool production is changing.

We don't have the results from the study yet.

We're just analyzing the wool.

But there's a lot of benefits in looking at animal models from a topical perspective and looking at topical senolytics as an avenue.

Hair loss is another big area that I think is understudied.

And there's a lot of potential by understanding pathways in senescence and how senescence pathways, we actually call them pathways.

you know, senescence-induced alopecia in a lot of our studies because there is a high concentration of senescent cells that accumulate with hair follicles on age-related hair loss.